Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?

Breast Cancer Research

Volumn 14, Issue 5, 2012, Pages

  Steinman, Richard A ^a,b   Brufsky, Adam M ^a   Oesterreich, Steffi ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; ESTROGEN; GOSERELIN; HEAT SHOCK PROTEIN 27; INTEGRIN; INTEGRIN 5; PROGESTERONE; TAMOXIFEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; SIGNAL PEPTIDE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MICROENVIRONMENT; NATURAL KILLER CELL; POLARIZATION; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN PRENYLATION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; BONE; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CELL MOVEMENT; DIPHOSPHONATES; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; HUMANS; IMIDAZOLES; IMMUNITY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84866857725     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3223     Document Type: Review

References (72)

1. Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP, McCloskey E, Coleman RE. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 2007, 13(18 Pt 1):5406-5410.
2. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res 2010, 12:214. 10.1186/bcr2769, 3046431, 21176176.
3. Aapro M, Saad F, Costa L. Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist 2010, 15:1147-1158. 10.1634/theoncologist.2007-0245, 3227909, 21051658.
4. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12:631-641. 10.1016/S1470-2045(11)70122-X, 21641868.
5. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011, 365:1396-1405. 10.1056/NEJMoa1105195, 21995387.
6. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010, 21:2188-2194. 10.1093/annonc/mdq217, 20444845.
7. Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012, 118:1192-1201. 10.1002/cncr.26313, 21987386.
8. Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 2009, 117:603-609. 10.1007/s10549-009-0332-2, 19214743.
9. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 2012, 12:40-48. 10.1016/j.clbc.2011.08.002, 22014381.
10. Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009, 44:908-916. 10.1016/j.bone.2009.01.010, 2782613, 19442620.
11. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007, 12:1035-1043. 10.1634/theoncologist.12-9-1035, 17914073.
12. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996, 98:698-705. 10.1172/JCI118841, 507479, 8698861.
13. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 291:680-686. 10.1006/bbrc.2002.6510, 11855844.
14. Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X, Pierga JY. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008, 14:3306-3311. 10.1158/1078-0432.CCR-07-4749, 18519757.
15. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428. 10.1016/S1470-2045(10)70054-1, 20362507.
16. Rack B, Juckstock J, Genss EM, Schoberth A, Schindlbeck C, Strobl B, Heinrigs M, Rammel G, Zwingers T, Sommer H, Friese K, Janni W. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010, 30:1807-1813.
17. Yokota A, Kimura S, Tanaka R, Takeuchi M, Yao H, Sakai K, Nagao R, Kuroda J, Kamitsuji Y, Kawata E, Ashihara E, Maekawa T. Osteoclasts are involved in the maintenance of dormant leukemic cells. Leuk Res 2010, 34:793-799. 10.1016/j.leukres.2009.08.034, 19781772.
18. Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011, 19:192-205. 10.1016/j.ccr.2010.12.022, 3040415, 21295524.
19. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846. 10.1038/nature02040, 14574413.
20. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007, 130:811-823. 10.1016/j.cell.2007.07.025, 17803905.
21. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935. 10.1200/JCO.2005.06.091, 15983391.
22. Liu CC, Howard GA. Bone-cell changes in estrogen-induced bone-mass increase in mice: dissociation of osteoclasts from bone surfaces. Anat Rec 1991, 229:240-250. 10.1002/ar.1092290211, 2012311.
23. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006, 66:4553-4557. 10.1158/0008-5472.CAN-05-3986, 16651403.
24. McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep 2009, 7:134-139. 10.1007/s11914-009-0023-2, 19968917.
25. Houghton J, Li H, Fan X, Liu Y, Liu JH, Rao VP, Poutahidis T, Taylor CL, Jackson EA, Hewes C, Lyle S, Cerny A, Bowen G, Cerny J, Moore N, Kurt-Jones EA, Erdman SE. Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev 2010, 19:1153-1166. 10.1089/scd.2009.0439, 3135253, 20199238.
26. Gnant M. Zoledronic acid in breast cancer: latest findings and interpretations. Ther Adv Med Oncol 2011, 3:293-301. 10.1177/1758834011420599, 3210470, 22084643.
27. Nicks KM, Perrien DS, Akel NS, Suva LJ, Gaddy D. Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, activin and inhibin. Mol Cell Endocrinol 2009, 310:11-20. 10.1016/j.mce.2009.07.001, 2951729, 19615428.
28. Mylonas I, Jeschke U, Shabani N, Kuhn C, Friese K, Gerber B. Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis. Oncol Rep 2005, 13:81-88.
29. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003, 9:2893-2897.
30. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Monkkonen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010, 14:2803-2815. 10.1111/j.1582-4934.2009.00926.x, 19818098.
31. Bausero P, Ben-Mahdi M, Mazucatelli J, Bloy C, Perrot-Applanat M. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am J Physiol Heart Circ Physiol 2000, 279:H2033-H2042.
32. Dadiani M, Seger D, Kreizman T, Badikhi D, Margalit R, Eilam R, Degani H. Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor alpha and c-Myc. Endocr Relat Cancer 2009, 16:819-834. 10.1677/ERC-08-0249, 19398483.
33. Saarinen NM, Abrahamsson A, Dabrosin C. Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo. Int J Cancer 2010, 127:737-745. 10.1002/ijc.25052, 19924815.
34. Sisci D, Middea E, Morelli C, Lanzino M, Aquila S, Rizza P, Catalano S, Casaburi I, Maggiolini M, Ando S. 17β-estradiol enhances alpha(5) integrin subunit gene expression through ERα-Sp1 interaction and reduces cell motility and invasion of ERα-positive breast cancer cells. Breast Cancer Res Treat 2010, 124:63-77. 10.1007/s10549-009-0713-6, 20052536.
35. Bellahcene A, Chaplet M, Bonjean K, Castronovo V. Zoledronate inhibits αvβ3 and αvβ5 integrin cell surface expression in endothelial cells. Endothelium 2007, 14:123-130. 10.1080/10623320701347187, 17497369.
36. Tsagozis P, Eriksson F, Pisa P. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol Immunother 2008, 57:1451-1459. 10.1007/s00262-008-0482-9, 18297280.
37. Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med 2011, 9:177. 10.1186/1479-5876-9-177, 3215187, 22005011.
38. Bengtsson AK, Ryan EJ, Giordano D, Magaletti DM, Clark EA. 17β-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood 2004, 104:1404-1410. 10.1182/blood-2003-10-3380, 15142882.
39. Hsieh YC, Frink M, Hsieh CH, Choudhry MA, Schwacha MG, Bland KI, Chaudry IH. Downregulation of migration inhibitory factor is critical for estrogen-mediated attenuation of lung tissue damage following trauma-hemorrhage. Am J Physiol Lung Cell Mol Physiol 2007, 292:L1227-L1232. 10.1152/ajplung.00479.2006, 17277045.
40. Routley CE, Ashcroft GS. Effect of estrogen and progesterone on macrophage activation during wound healing. Wound Repair Regen 2009, 17:42-50. 10.1111/j.1524-475X.2008.00440.x, 19152650.
41. Menzies FM, Henriquez FL, Alexander J, Roberts CW. Selective inhibition and augmentation of alternative macrophage activation by progesterone. Immunology 2011, 134:281-291. 10.1111/j.1365-2567.2011.03488.x, 21977998.
42. Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J, Touraine JL, Clezardin P. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vγ9Vδ2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 2011, 71:4562-4572. 10.1158/0008-5472.CAN-10-3862, 21646473.
43. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003, 102:2310-2311. 10.1182/blood-2003-05-1655, 12959943.
44. Nussbaumer O, Gruenbacher G, Gander H, Thurnher M. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes. Blood 2011, 118:2743-2751. 10.1182/blood-2011-01-328526, 21673342.
45. Friedl A, Jordan VC. Oestradiol stimulates growth of oestrogen receptor-negative MDA-MB-231 breast cancer cells in immunodeficient mice by reducing cell loss. Eur J Cancer 1994, 30A:1559-1564.
46. Jiang X, Ellison SJ, Alarid ET, Shapiro DJ. Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene 2007, 26:4106-4114. 10.1038/sj.onc.1210197, 17237823.
47. Dosiou C, Hamilton AE, Pang Y, Overgaard MT, Tulac S, Dong J, Thomas P, Giudice LC. Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone. J Endocrinol 2008, 196:67-77. 10.1677/JOE-07-0317, 18180318.
48. Check JH, Sansoucie L, Chern J, Dix E. Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res 2010, 30:119-122.
49. Gallo M, De Luca A, Lamura L, Normanno N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 2012, 23:597-604. 10.1093/annonc/mdr159, 21551002.
50. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563. 10.1038/nature06188, 17914389.
51. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004, 10:4559-4567. 10.1158/1078-0432.CCR-03-0325, 15240548.
52. Hasmim M, Bieler G, Ruegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 2007, 5:166-173. 10.1111/j.1538-7836.2006.02259.x, 17059425.
53. Wu Q, Chambliss K, Umetani M, Mineo C, Shaul PW. Non-nuclear estrogen receptor signaling in the endothelium. J Biol Chem 2011, 286:14737-14743. 10.1074/jbc.R110.191791, 3083154, 21343284.
54. Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat 2010, 121:293-300. 10.1007/s10549-009-0458-2, 19597705.
55. Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, Biglia N, Sismondi P, Genazzani AR, Simoncini T. Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One 2008, 3:e2238. 10.1371/journal.pone.0002238, 2375059, 18493596.
56. Fromigue O, Kheddoumi N, Body JJ. Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br J Cancer 2003, 89:178-184. 10.1038/sj.bjc.6601009, 2394205, 12838321.
57. Moschetta M, Di Pietro G, Ria R, Gnoni A, Mangialardi G, Guarini A, Ditonno P, Musto P, D'Auria F, Ricciardi MR, Dammacco F, Ribatti D, Vacca A. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 2010, 46:420-429. 10.1016/j.ejca.2009.10.019, 19914061.
58. Khan KN, Masuzaki H, Fujishita A, Kitajima M, Sekine I, Matsuyama T, Ishimaru T. Estrogen and progesterone receptor expression in macrophages and regulation of hepatocyte growth factor by ovarian steroids in women with endometriosis. Hum Reprod 2005, 20:2004-2013. 10.1093/humrep/deh897, 15831511.
59. Zhang HZ, Bennett JM, Smith KT, Sunil N, Haslam SZ. Estrogen mediates mammary epithelial cell proliferation in serum-free culture indirectly via mammary stroma-derived hepatocyte growth factor. Endocrinology 2002, 143:3427-3434. 10.1210/en.2002-220007, 12193555.
60. Rodrigues GA, Park M, Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J 1997, 16:2634-2645. 10.1093/emboj/16.10.2634, 1169874, 9184210.
61. Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, Kuperwasser C. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 2007, 67:2062-2071. 10.1158/0008-5472.CAN-06-3895, 17332335.
62. Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirstrom K, Magnusson K, Ebert BL, Ponten F, Weinberg RA, McAllister SS. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011, 121:784-799. 10.1172/JCI43757, 3026724, 21266779.
63. Lu R, Serrero G. Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor). Proc Natl Acad Sci USA 2001, 98:142-147. 10.1073/pnas.98.1.142, 14558, 11134521.
64. Kars MD, Iseri OD, Ural AU, Gunduz U. In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res 2007, 27:4031-4037.
65. Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Redini F, Rogers M, Heymann D. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med 2008, 12:928-941. 10.1111/j.1582-4934.2008.00141.x, 18494934.
66. Morii T, Ohtsuka K, Ohnishi H, Mochizuki K, Satomi K. Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid. Anticancer Res 2010, 30:3565-3571.
67. Porter W, Saville B, Hoivik D, Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 1997, 11:1569-1580. 10.1210/me.11.11.1569, 9328340.
68. Cooper LF, Tiffee JC, Griffin JP, Hamano H, Guo Z. Estrogen-induced resistance to osteoblast apoptosis is associated with increased hsp27 expression. J Cell Physiol 2000, 185:401-407. 10.1002/1097-4652(200012)185:3<401::AID-JCP10>3.0.CO;2-C, 11056010.
69. Dalenc F, Giamarchi C, Petit M, Poirot M, Favre G, Faye JC. Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Res 2005, 7:R1159-R1167. 10.1186/bcr1357, 1410750, 16457696.
70. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009, 15:68-74. 10.1038/nm.1908, 19122658.
71. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE, Swain SM, Contantino JP, Mamounas EP, Wolmark N. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012, , http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70226-7/fulltext#article_upsell
72. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102:1099-1105. 10.1038/sj.bjc.6605604, 2853093, 20234364.